Tokyo Tape
Sign in
← Chiome Bioscience

Quarterly report · Q1

4583.TEDINET S100QPID
Period2023-01-01 → 2023-03-31
Filed2023-05-11
StandardJapan GAAP
ConsolidatedNo
Data checks10 of 10 passed
Key figures · 32
MetricValuePeriodScopeSource row
Revenue¥169m2023-01-01 → 2023-03-31StandaloneNet sales
Revenue¥631m2022-01-01 → 2022-12-31StandaloneNet sales (5-year summary)
Revenue¥129m2022-01-01 → 2022-03-31StandaloneNet sales
Operating income−¥226m2023-01-01 → 2023-03-31StandaloneOperating income
Operating income−¥487m2022-01-01 → 2022-03-31StandaloneOperating income
Ordinary income−¥227m2023-01-01 → 2023-03-31StandaloneOrdinary income
Ordinary income−¥1.2bn2022-01-01 → 2022-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥491m2022-01-01 → 2022-03-31StandaloneOrdinary income
Profit before tax−¥226m2023-01-01 → 2023-03-31StandaloneIncome before income taxes
Profit before tax−¥491m2022-01-01 → 2022-03-31StandaloneIncome before income taxes
Net income−¥228m2023-01-01 → 2023-03-31StandaloneProfit loss
Net income−¥1.2bn2022-01-01 → 2022-12-31StandaloneNet income loss (5-year summary)
Net income−¥492m2022-01-01 → 2022-03-31StandaloneProfit loss
Total assets¥2.1bnat 2023-03-31StandaloneAssets
Total assets¥2.2bnat 2022-12-31StandaloneAssets
Total assets¥2.1bnat 2022-03-31StandaloneTotal assets (5-year summary)
Total liabilities¥524mat 2023-03-31StandaloneLiabilities
Total liabilities¥425mat 2022-12-31StandaloneLiabilities
Net assets / equity¥1.6bnat 2023-03-31StandaloneNet assets
Net assets / equity¥1.8bnat 2022-12-31StandaloneNet assets
Net assets / equity¥1.7bnat 2022-03-31StandaloneNet assets (5-year summary)
Cash and deposits¥1.6bnat 2023-03-31StandaloneCash and deposits
Cash and deposits¥1.7bnat 2022-12-31StandaloneCash and deposits
EPS (basic)¥-4.72023-01-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-28.262022-01-01 → 2022-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-11.662022-01-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
Equity ratio74.3%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio80.2%at 2022-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.3%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
Shares issued48,423,500at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued48,423,500at 2022-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued42,409,900at 2022-03-31StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥128m
jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2023-01-01 → 2023-03-31−¥194m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue2023-01-01 → 2023-03-31¥169m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue external2023-01-01 → 2023-03-31¥169m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentsegment profit2023-01-01 → 2023-03-31¥96m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-03-31¥169m
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-03-31¥169m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-03-31−¥98m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-03-31−¥111m
jpcrp040300-q1r_E26096-000Drug Discovery And Developmentreportable segmentsegment profit2022-01-01 → 2022-03-31−¥446m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue2022-01-01 → 2022-03-31¥129m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentrevenue external2022-01-01 → 2022-03-31¥129m
jpcrp040300-q1r_E26096-000Drug Discovery Supportreportable segmentsegment profit2022-01-01 → 2022-03-31¥71m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-03-31¥129m
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-03-31¥129m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-03-31−¥375m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 321
ItemContextValueUnit
Noncurrent assetsCurrentQuarterInstant_NonConsolidatedMember120901000JPY
AssetsPrior1YearInstant_NonConsolidatedMember2215470000JPY
AssetsCurrentQuarterInstant_NonConsolidatedMember2085676000JPY
Accounts payable tradePrior1YearInstant_NonConsolidatedMember31866000JPY
Accounts payable tradeCurrentQuarterInstant_NonConsolidatedMember49143000JPY
Short term loans payablePrior1YearInstant_NonConsolidatedMember184000000JPY
Short term loans payableCurrentQuarterInstant_NonConsolidatedMember301000000JPY
Accounts payable otherPrior1YearInstant_NonConsolidatedMember70800000JPY
Accounts payable otherCurrentQuarterInstant_NonConsolidatedMember56191000JPY
Accrued expensesPrior1YearInstant_NonConsolidatedMember26558000JPY
Accrued expensesCurrentQuarterInstant_NonConsolidatedMember21379000JPY
Income taxes payablePrior1YearInstant_NonConsolidatedMember23943000JPY
Income taxes payableCurrentQuarterInstant_NonConsolidatedMember9193000JPY
Advances receivedPrior1YearInstant_NonConsolidatedMember22100000JPY
Advances receivedCurrentQuarterInstant_NonConsolidatedMember22100000JPY
Deposits receivedPrior1YearInstant_NonConsolidatedMember4835000JPY
Deposits receivedCurrentQuarterInstant_NonConsolidatedMember6746000JPY
Provision for bonusesPrior1YearInstant_NonConsolidatedMember6351000JPY
Provision for bonusesCurrentQuarterInstant_NonConsolidatedMember3413000JPY
Current liabilitiesPrior1YearInstant_NonConsolidatedMember370455000JPY
Current liabilitiesCurrentQuarterInstant_NonConsolidatedMember469169000JPY
Asset retirement obligations nclPrior1YearInstant_NonConsolidatedMember54268000JPY
Asset retirement obligations nclCurrentQuarterInstant_NonConsolidatedMember54374000JPY
Noncurrent liabilitiesPrior1YearInstant_NonConsolidatedMember54268000JPY
Noncurrent liabilitiesCurrentQuarterInstant_NonConsolidatedMember54374000JPY
LiabilitiesPrior1YearInstant_NonConsolidatedMember424724000JPY
LiabilitiesCurrentQuarterInstant_NonConsolidatedMember523544000JPY
Capital stockPrior1YearInstant_NonConsolidatedMember2097017000JPY
Capital stockCurrentQuarterInstant_NonConsolidatedMember2097017000JPY
Capital surplusPrior1YearInstant_NonConsolidatedMember3696798000JPY
Capital surplusCurrentQuarterInstant_NonConsolidatedMember3696798000JPY
Retained earningsPrior1YearInstant_NonConsolidatedMember-4016331000JPY
Retained earningsCurrentQuarterInstant_NonConsolidatedMember-4244014000JPY
Treasury stockPrior1YearInstant_NonConsolidatedMember-292000JPY
Treasury stockCurrentQuarterInstant_NonConsolidatedMember-292000JPY
Shareholders equityPrior1YearInstant_NonConsolidatedMember1777192000JPY
Shareholders equityCurrentQuarterInstant_NonConsolidatedMember1549508000JPY
Subscription rights to sharesPrior1YearInstant_NonConsolidatedMember13554000JPY
Subscription rights to sharesCurrentQuarterInstant_NonConsolidatedMember12624000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember1790746000JPY
Net assetsCurrentQuarterInstant_NonConsolidatedMember1562132000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember2215470000JPY
Liabilities and net assetsCurrentQuarterInstant_NonConsolidatedMember2085676000JPY
Net salesPrior1YTDDuration_NonConsolidatedMember128571000JPY
Net salesCurrentYTDDuration_NonConsolidatedMember169404000JPY
Cost of salesPrior1YTDDuration_NonConsolidatedMember57730000JPY
Cost of salesCurrentYTDDuration_NonConsolidatedMember73464000JPY
Gross profitPrior1YTDDuration_NonConsolidatedMember70840000JPY
Gross profitCurrentYTDDuration_NonConsolidatedMember95940000JPY
Research and development expenses sgaPrior1YTDDuration_NonConsolidatedMember446004000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identitynon_consolidated 2022-12-31pass
balance sheet identitynon_consolidated 2023-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · revenuenon_consolidated 2022-01-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-03-31pass
statement vs summary · total assetsnon_consolidated 2022-12-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass